Heba Agha
Regulatory
Dr. Hebaalla Agha is a Regulatory Affairs Specialist at EIT Pharma, Inc., supporting the NDA submission for lonafarnib for HDV, clinical research activities, and the clinical hold lift for Lambda. She brings a strong scientific foundation in pharmaceutical sciences and hands-on experience in drug discovery and development, helping translate research into real-world treatments. Dr. Agha earned her Ph.D. in Medicinal Chemistry from the University of Florida and her M.Sc. in Pharmaceutical Sciences from Cairo University, where she also completed her undergraduate pharmacy degree with honor distinction. She is an inventor on an international patent application stemming from her doctoral research. Before joining EIT Pharma, Dr. Agha conducted postdoctoral research at the Structural Genomics Consortium (SGC-UNC) at the University of North Carolina at Chapel Hill, contributing to NIH-funded antiviral drug discovery projects, and gained industry experience at Bristol Myers Squibb. She is passionate about translating scientific innovation into impactful therapeutic development.